1-19 of 19
John Sarantopoulos
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody–Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors

Matteo Duca, Darren Wan-Teck Lim, Vivek Subbiah, Shunji Takahashi, John Sarantopoulos, Andrea Varga, Joseph A. D'Alessio, Tinya Abrams, Qing Sheng, Eugene Youchin Tan, Maria Santos Rosa, Juan Gonzalez-Maffe, Janna Sand-Dejmek, Claire Fabre, Miguel Martin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (4): 625–634.
https://doi.org/10.1158/1535-7163.MCT-21-0652
Published: 01 April 2022
View article titled, A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody–Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
Open the PDF for A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody–Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors in another window
Journal Articles

Abstract B29: A multicenter, open-label phase 1/2 study of oral CFG920, in combination with prednisone in adult patients with metastatic castration-resistant prostate cancer

Sebastien J. Hotte, Joan Carles, John Sarantopoulos, Charles J. Ryan, Joshua M. Lang, Bruce Montgomery, Koichi Fukino, Gwendolyn Gobbo, Xiaoming Cui, Prakash Mistry, Chun Pan, Jean-Pascal Machiels
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B29.
https://doi.org/10.1158/1535-7163.TARG-15-B29
Published: 01 December 2015
View article titled, Abstract B29: A multicenter, open-label phase 1/2 study of oral CFG920, in combination with prednisone in adult patients with metastatic castration-resistant prostate cancer
Journal Articles

Abstract A3: Beyond VEGF inhibition: Comparative efficacy analysis of novel VEGF and non-VEGF therapeutic agents in phase I trials for patients with metastatic colorectal cancer.

Sukeshi R. Patel, Anand B. Karnad, Norma S. Ketchum, Brad H. Pollock, John Sarantopoulos, Steven Weitman, Devalingam Mahalingam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A3.
https://doi.org/10.1158/1535-7163.TARG-13-A3
Published: 01 November 2013
View article titled, Abstract A3: Beyond VEGF inhibition: Comparative efficacy analysis of novel VEGF and non-VEGF therapeutic agents in phase I trials for patients with metastatic colorectal cancer.
Journal Articles

Abstract A70: Clinical outcomes and survival of advanced renal cancer patients in Phase I clinical trials.

Laeeq Malik, Helen Parsons, Devalingam Mahalingam, Benjamin Ehler, Martin Goros, Andrew Brenner, John Sarantopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A70.
https://doi.org/10.1158/1535-7163.TARG-13-A70
Published: 01 November 2013
View article titled, Abstract A70: Clinical outcomes and survival of advanced renal cancer patients in Phase I clinical trials.
Journal Articles

Abstract C242: A phase 1/1b dose escalation study of iniparib as a single agent and in combination with gemcitabine/carboplatin in patients with advanced solid tumors.

Monica Mita, Raffaele Baffa, Eric Charpentier, Craig A. Lockhart, John C. Morris, Olivier Rixe, John Sarantopoulos, Ramesh Ramanathan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C242.
https://doi.org/10.1158/1535-7163.TARG-13-C242
Published: 01 November 2013
View article titled, Abstract C242: A phase 1/1b dose escalation study of iniparib as a single agent and in combination with gemcitabine/carboplatin in patients with advanced solid tumors.
Journal Articles

Abstract B244: A first-in-human phase 1 clinical study of G-202, a thapsigargin-based Prostate-Specific Membrane Antigen (PSMA) activated prodrug, in patients with advanced solid tumors.

Devalingam Mahalingam, Jeremy Cetnar, George Wilding, Samuel Denmeade, John Sarantopoulos, Michael Kurman, Michael Carducci
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B244.
https://doi.org/10.1158/1535-7163.TARG-13-B244
Published: 01 November 2013
View article titled, Abstract B244: A first-in-human phase 1 clinical study of G-202, a thapsigargin-based Prostate-Specific Membrane Antigen (PSMA) activated prodrug, in patients with advanced solid tumors.
Journal Articles

Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors

Razelle Kurzrock, Nash Gabrail, Chandtip Chandhasin, Stacy Moulder, Carrie Smith, Andrew Brenner, Kamalesh Sankhala, Alain Mita, Kelly Elian, Danielle Bouchard, John Sarantopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 308–316.
https://doi.org/10.1158/1535-7163.MCT-11-0566
Published: 08 February 2012
View article titled, Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors
Open the PDF for Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors in another window
Journal Articles

Abstract A113: ATI-1123, a novel human albumin-stabilized docetaxel liposomal formulation: Final results of a phase I study in patients with advanced solid malignancies.

Alain C. Mita, Neil N. Senzer, Sushma Vemulapalli, John Sarantopoulos, Devalingam Mahalingam, Monica M. Mita, Jessica Hart, Nicole S. Gallegos, Gavin Anderson, John Charles, Ahmed Kosuba, Jon M. Rogers, John J. Nemunaitis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A113.
https://doi.org/10.1158/1535-7163.TARG-11-A113
Published: 12 November 2011
View article titled, Abstract A113: ATI-1123, a novel human albumin-stabilized docetaxel liposomal formulation: Final results of a phase I study in patients with advanced solid malignancies.
Journal Articles

Abstract B191: Phase 1 pharmacokinetic (PK) assessments of ATI-1123, a novel human serum albumin-stabilized nanoparticle docetaxel liposomal formulation, in patients with advanced solid malignancies.

Devalingam Mahalingam, Alain Mita, Ahmed Kousba, Sushma Vemulapalli, Nicole Gallegos, Gavin Anderson, J. Charles, Jon M. Rogers, John Sarantopoulos, Monica Mita, Neil Senzer, John Nemunaitis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B191.
https://doi.org/10.1158/1535-7163.TARG-11-B191
Published: 12 November 2011
View article titled, Abstract B191: Phase 1 pharmacokinetic (PK) assessments of ATI-1123, a novel human serum albumin-stabilized nanoparticle docetaxel liposomal formulation, in patients with advanced solid malignancies.
Journal Articles

Abstract B194: Phase 1 relative bioavailability study of a prototype oral solution (OS) formulation of the investigational Aurora A kinase (AAK) inhibitor alisertib (MLN8237) in reference to a powder-in-capsule (PIC) formulation in patients with advanced solid tumors.

Gerald S. Falchook, John Sarantopoulos, Razelle Kurzrock, Alain C. Mita, Siqing Fu, Monica M. Mita, Xiaofei Zhou, Catherine Milch, JungAh Jung, Karthik Venkatakrishnan, Lee S. Rosen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B194.
https://doi.org/10.1158/1535-7163.TARG-11-B194
Published: 12 November 2011
View article titled, Abstract B194: Phase 1 relative bioavailability study of a prototype oral solution (OS) formulation of the investigational Aurora A kinase (AAK) inhibitor alisertib (MLN8237) in reference to a powder-in-capsule (PIC) formulation in patients with advanced solid tumors.
Journal Articles

Abstract B185: Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with temozolomide (TMZ) in patients with advanced solid tumors.

Alain C. Mita, Monica M. Mita, John Sarantopoulos, Julie C. Martin, Janet D. Kueber, Sharon McGonigle, Mark Matijevic, Bipin Mistry, Javier L. Ferrada, Pallavi Sachdev, Joe J. Stephenson, Jr.
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B185.
https://doi.org/10.1158/1535-7163.TARG-11-B185
Published: 12 November 2011
View article titled, Abstract B185: Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with temozolomide (TMZ) in patients with advanced solid tumors.
Journal Articles

Abstract A38: Development and implementation of immunohistochemistry (IHC)-based pharmacodynamic (PD) biomarkers demonstrate NAE pathway inhibition in MLN4924 solid tumor clinical trials.

Alice A. McDonald, Kristine Burke, Michael Thomas, Alison Berger, Peter G. Smith, Stephen Tirrell, Stephen J. Blakemore, Geogre Mulligan, Michael D. Pickard, Mark D. Fleming, John S. Kauh, John Sarantopoulos, Bruce J. Dezube, Bradley Stringer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A38.
https://doi.org/10.1158/1535-7163.TARG-11-A38
Published: 12 November 2011
View article titled, Abstract A38: Development and implementation of immunohistochemistry (IHC)-based pharmacodynamic (PD) biomarkers demonstrate NAE pathway inhibition in MLN4924 solid tumor clinical trials.
Journal Articles

Abstract B49: GRN1005 phase I studies: Final results.

Patrick Y. Wen, Jan Drappatz, Andrew Brenner, Tom Mikkelsen, David Schiff, Steven Rosenfeld, Morris Groves, Yijing Shen, Xiaolin Wang, Mona Shing, Betty Lawrence, Jean-Paul Castaigne, Nash Gabrail, John Sarantopoulos, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B49.
https://doi.org/10.1158/1535-7163.TARG-11-B49
Published: 12 November 2011
View article titled, Abstract B49: GRN1005 phase I studies: Final results.
Journal Articles

Abstract B55: A study of REOLYSIN in combination with gemcitabine in patients with advanced pancreatic adenocarcinoma.

Monica M. Mita, Yubao Wang, John Sarantopoulos, Sushma Vemulapalli, Benjamin George, Alain Mita, Mattew Coffey, George Gill, Devaligam Mahaligam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B55.
https://doi.org/10.1158/1535-7163.TARG-11-B55
Published: 12 November 2011
View article titled, Abstract B55: A study of REOLYSIN in combination with gemcitabine in patients with advanced pancreatic adenocarcinoma.
Journal Articles

Abstract B6: A phase II study of the efficacy and safety of foretinib, a novel receptor tyrosine kinase inhibitor, given on an intermittent 5‐days‐on/9‐days‐off (5/9) schedule in patients with recurrent or metastatic squamous cell cancer of the head and neck

Tanguy Seiwert, Suzanne Swann, Hazel Kurz, Peter Bonate, Stewart McCallum, John Sarantopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B6.
https://doi.org/10.1158/1535-7163.TARG-09-B6
Published: 10 December 2009
View article titled, Abstract B6: A phase II study of the efficacy and safety of foretinib, a novel receptor tyrosine kinase inhibitor, given on an intermittent 5‐days‐on/9‐days‐off (5/9) schedule in patients with recurrent or metastatic squamous cell cancer of the head and neck
Journal Articles

Abstract B168: ANG1005: Results of a phase I study in patients with advanced solid tumors and metastatic brain cancer

Razelle Kurzrock, Nash Gabrail, Stacy Moulder, Cherie Noles, Carrie Smith, Zhong Guo, Danielle Bouchard, Wendy Churchill, Paula Bento, Ann Neale, Jean‐Paul Castaigne, John Sarantopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B168.
https://doi.org/10.1158/1535-7163.TARG-09-B168
Published: 10 December 2009
View article titled, Abstract B168: ANG1005: Results of a phase I study in patients with advanced solid tumors and metastatic brain cancer
Journal Articles

A phase I and pharmacokinetic study of a CanAg-targeted immunoconjugate, HuC242-DM4, in patients with CanAg-expressing solid tumors

Kamalesh Sankhala, Alain Mita, Alejandro Ricart, Monica Mita, Chia Lin, Leslie Wood, John Sarantopoulos, Chris Takimoto, Amita Patnaik, Albert Qin, Sybil Zildjian, Anthony Tolcher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B70.
Published: 01 November 2007
View article titled, A phase I and pharmacokinetic study of a CanAg-targeted immunoconjugate, HuC242-DM4, in patients with CanAg-expressing solid tumors
Journal Articles

A phase I and pharmacokinetic (PK) study of vinorelbine liposomes injection in patients with advanced solid tumors, non-Hodgkin’s lymphoma, and Hodgkin’s disease

Gerald Batist, Anthony Tolcher, John Sarantopoulos, Kamalesh Sankhala, Jeannie Fontanilla, Biao Lu, Gavin Choy, Steven Deitcher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A150.
Published: 01 November 2007
View article titled, A phase I and pharmacokinetic (PK) study of vinorelbine liposomes injection in patients with advanced solid tumors, non-Hodgkin’s lymphoma, and Hodgkin’s disease
Journal Articles

A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of GTI2040 (GTI), a novel ribonucleotide reductase inhibitor in combination with gemcitabine (Gem) in adult patients (pts) with advanced solid tumors.

Chris Takimoto, Quincy Chu, Yun Yen, Patricia O'Rourke, Joshua Cooper, Sam Pardo, Anthony Tolcher, Amita Patnaik, Kyriakos Papadopoulos, Muralidhar Beeram, Alejandro Ricart, Chia-Chi Lin, Alain Mita, Emiliano Calvo, Igor Espinoza-Delgado, Jamie Zwiebel, John Sarantopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C160.
Published: 01 November 2007
View article titled, A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of GTI2040 (GTI), a novel ribonucleotide reductase inhibitor in combination with gemcitabine (Gem) in adult patients (pts) with advanced solid tumors.